TSE:GEN GeneNews (GEN) Stock Price, News & Analysis → New trading system called MSFT, NVDA & MSFT (From WealthPress) (Ad) Free GEN Stock Alerts C$0.15 +0.01 (+7.14%) (As of 06/25/2019) Add Compare Share Share Today's RangeC$0.14▼C$0.1550-Day RangeC$0.15▼C$0.1552-Week RangeC$0.03▼C$0.21Volume473,147 shsAverage Volume1.48 million shsMarket CapitalizationC$25.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GeneNews alerts: Email Address Ad Daily Strike Alliance🚀 Tap into this explosive trade opportunity asapI learned about these explosive stocks during my two decades on Wall Street… And used them to help grow my old hedge fund from just a few million to over $700 million dollars*. So it’s safe to say… these bad boys work. What’s the secret behind these special trades? Well, right now, I’m going public with the unique strategy behind these “Calendar Stocks”…Go here to see how you can exploit my next “Calendar Stock”. About GeneNews Stock (TSE:GEN)GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.Read More GEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GEN Stock News HeadlinesMay 16, 2024 | washingtonpost.comGeneNews: Q1 Earnings SnapshotJanuary 18, 2024 | msn.comVertex, Crispr Get Second FDA Approval for Gene TherapyJanuary 17, 2024 | msn.comGene-editing treatment from Vertex and CRISPR cleared for second rare blood disorderJanuary 17, 2024 | msn.comFDA expands use of newly approved CRISPR therapyJanuary 16, 2024 | washingtonpost.comOhio St hires Texas A&M athletic director Ross Bjork to replace the retiring Gene SmithNovember 27, 2023 | msn.comMutated gene thought to exist in just 4% of people could ‘help tackle obesity’November 18, 2023 | nytimes.comSickle-Cell Treatment Created With Gene Editing Wins U.K. ApprovalNovember 17, 2023 | msn.comUK authorizes gene therapy for blood disorders in world firstNovember 16, 2023 | msn.comMac Jones Losing Support of Patriots Teammates After Being Benched for Third Time, ReportNovember 16, 2023 | usatoday.comGene Frenette: Mac Jones' decline with Patriots also a product of Bill Belichick negligenceOctober 31, 2023 | msn.comSarepta Seeks Broader Approval for Gene Therapy Even After Drug Trial FizzledOctober 31, 2023 | wsj.comSarepta Therapeutics Stock Dives After New Gene Therapy DataOctober 31, 2023 | msn.comFDA panel considers gene therapy as a potential cure for the sickest sickle cell patientsMarch 27, 2023 | marketwatch.comOncology Molecular Diagnostics Market by 2031March 19, 2023 | marketwatch.comGlobal Colorectal Cancer Diagnostic Market Industry Insights, Drivers, Top Trends, Global Analysis, Forecast and Opportunities to 2030 By VMReportsJanuary 5, 2023 | thestreet.comBiotech Stock Mailbag: GenVecFebruary 23, 2022 | investing.comStageZero Life Sciences Ltd (SZLS)See More Headlines Receive GEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolTSE:GEN CUSIPN/A CIKN/A Webwww.genenews.com Phone+1-905-7392030FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.05 Sales & Book Value Annual SalesC$234,592.00 Price / Sales108.68 Cash FlowC$0.00 per share Price / Cash Flow145.00 Book ValueC($0.06) per share Price / Book-2.68Miscellaneous Outstanding Shares169,963,000Free FloatN/AMarket CapC$25.49 million OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. James R. Howard-TrippExec. Chairman & CEOMs. Joanna M. Halsey Esq.Gen. Counsel, Chief Compliance Officer & HR Director of IDLProf. Choong-Chin Liew Ph.D.Co-FounderMr. Warren Whitehead (Age 67)Chief Accountant Mr. David SuriaSr. ScientistKey CompetitorsLED Medical DiagnosticsCVE:LMDLexaGeneCVE:LXGAkuminTSE:AKUAptose BiosciencesTSE:APSAcasti PharmaCVE:ACSTView All Competitors GEN Stock Analysis - Frequently Asked Questions How have GEN shares performed in 2024? GeneNews' stock was trading at C$0.15 at the beginning of 2024. Since then, GEN stock has increased by 0.0% and is now trading at C$0.15. View the best growth stocks for 2024 here. What other stocks do shareholders of GeneNews own? Based on aggregate information from My MarketBeat watchlists, some companies that other GeneNews investors own include StorageVault Canada (SVI), American Airlines Group (AAL), Aareal Bank (ARL), Broadcom (AVGO), Aspen Technology (AZPN), British American Tobacco (BATS), Cronos Group (CRON) and Edwards Lifesciences (EW). How do I buy shares of GeneNews? Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:GEN) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneNews Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.